Proteomics Laboratory for Clinical and Translational Research, Charlotte, NC 28232, U.S.A.
Cancer Genomics Proteomics. 2012 Sep-Oct;9(5):257-63.
Pancreatic cancer is an aggressive disease with nearly equal yearly rates of diagnosis and death. Current therapies have failed to improve outcomes due to rapid disease progression and late stage at presentation. Recently, pathways involved in progression and metastasis have been elucidated; however, new knowledge has not generated more effective therapies. We report on the use of subcellular fractionation and liquid chromatography (LC)-mass spectrometry to identify 3,907 proteins in four pancreatic cancer cell lines, 540 of which are unique to primary cancer cells, and 487 unique to cells derived from metastatic sites. Statistical analysis identified 134 proteins significantly differentially expressed between the two populations. The subcellular localization of these proteins was determined and expression levels for four targets were validated using western blot techniques. These identified proteins can be further investigated to determine their roles in progression and metastasis and may serve as therapeutic targets in the development of more effective treatments for pancreatic cancer.
胰腺癌是一种侵袭性疾病，其诊断率和死亡率几乎相等。由于疾病进展迅速和就诊时已处于晚期，目前的治疗方法未能改善预后。最近，已阐明涉及进展和转移的途径；然而，新知识并未产生更有效的治疗方法。我们报告了使用亚细胞分级分离和液相色谱（LC）-质谱法在四种胰腺癌细胞系中鉴定出 3907 种蛋白质，其中 540 种是原发性癌细胞特有的，487 种是来源于转移部位的细胞特有的。统计分析确定了这两个群体之间有 134 种蛋白质的表达存在显著差异。确定了这些蛋白质的亚细胞定位，并使用 Western blot 技术验证了四个靶标蛋白的表达水平。可以进一步研究这些鉴定出的蛋白质，以确定它们在进展和转移中的作用，并可能作为开发更有效的胰腺癌治疗方法的治疗靶点。
